Create Free Account

By creating account you will get access to hot stocks & personalised emails

Avita Therapeutics Inc

Healthcare AU AVH

2.46AUD
-0.15(5.75%)

Last update at 2025-04-03T05:10:00Z

Day Range

2.442.54
LowHigh

52 Week Range

2.344.92
LowHigh

Fundamentals

  • Previous Close 2.61
  • Market Cap382.93M
  • Volume500881
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-55.46700M
  • Revenue TTM64.25M
  • Revenue Per Share TTM2.48
  • Gross Profit TTM 55.16M
  • Diluted EPS TTM-0.76

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -26.62900M -34.54513M -26.54500M -42.02600M -24.75004M
Minority interest - - - - -
Net income -26.66500M -34.60293M -26.58300M -42.03000M -24.62408M
Selling general administrative 23.33M 28.83M 22.40M 34.62M 12.67M
Selling and marketing expenses 21.91M 22.39M 14.66M 14.81M 12.31M
Gross profit 28.38M 37.05M 23.28M 11.29M 4.21M
Reconciled depreciation 0.57M - 0.71M 0.47M 0.26M
Ebit -27.50500M -34.51210M -27.23800M -41.99300M -24.98832M
Ebitda -26.04500M -33.58585M -26.52300M -41.52800M -24.72359M
Depreciation and amortization 1.46M 0.93M 0.71M 0.47M 0.26M
Non operating income net other - - - - -
Operating income -27.50500M -34.51210M -26.54000M -42.67900M -24.72359M
Other operating expenses 61.93M 63.16M 55.77M 56.94M 30.44M
Interest expense 0.02M 0.04M 0.02M 0.03M 0.03M
Tax provision 0.04M 0.03M 0.04M 0.00400M -0.17986M
Interest income 0.02M 0.02M 0.02M 0.03M -
Net interest income -0.01600M - -0.02200M -0.03300M -0.03777M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.04M 0.06M 0.04M 0.00400M -0.12597M
Total revenue 34.42M 45.45M 29.23M 14.26M 5.40M
Total operating expenses 55.88M 71.56M 49.82M 53.97M 29.25M
Cost of revenue 6.04M 8.40M 5.95M 2.97M 1.19M
Total other income expense net 0.88M -0.03303M 0.02M 0.69M 0.32M
Discontinued operations - - - 1.54M -8.56421M
Net income from continuing ops -26.66500M - -26.58300M -42.03000M -35.16023M
Net income applicable to common shares -26.66500M -28.85400M -26.58300M -42.03000M -25.10200M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 111.64M 98.26M 159.67M 125.50M 82.46M
Intangible assets 0.49M 0.47M 0.61M 0.47M 0.36M
Earning assets - - - - -
Other current assets - 1.03M 0.20M 1.33M 0.99M
Total liab 62.58M 13.52M 12.59M 9.85M 10.06M
Total stockholder equity 49.06M 84.74M -324.69670M 115.66M 72.40M
Deferred long term liab - - 0.50M 0.61M -
Other current liab 0.34M 6.88M 8.86M 4.27M 3.38M
Common stock - 0.00300M 0.00413M 0.00300M 0.00300M
Capital stock 0.00300M 0.00300M - 0.00300M 0.00300M
Retained earnings -297.96900M -262.58800M -324.70082M -221.49600M -194.91300M
Other liab - 2.52M 1.33M 1.58M 0.43M
Good will - - - - -
Other assets - 1.36M 1.30M 0.76M 0.00100M
Cash 22.12M 18.16M 76.40M 110.75M 73.64M
Cash and equivalents - - 55.51M 110.75M -
Total current liabilities 13.20M 10.69M 12.59M 7.39M 7.71M
Current deferred revenue - 0.19M - - -
Net debt 17.69M -17.24600M -76.39979M -109.86800M -71.72200M
Short term debt - 0.61M 0.00000M 0.00000M 0.00000M
Short long term debt - - - - -
Short long term debt total - 0.92M - 0.88M 1.92M
Other stockholder equity - 339.70M 324.70M 328.89M 259.17M
Property plant equipment - 2.05M 2.81M 2.94M 3.71M
Total current assets 104.01M 87.46M 126.80M 121.33M 78.39M
Long term investments 0.00000M 6.93M - - -
Net tangible assets - 84.28M 104.18M 115.18M 72.04M
Short term investments 66.94M 61.18M 40.81M - -
Net receivables 7.66M 4.96M 3.51M 7.40M 2.43M
Long term debt 39.81M - - - -
Inventory 5.60M 2.12M 2.93M 1.65M 1.12M
Accounts payable 3.79M 3.00M 3.73M 3.12M 4.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 7.63M - 8.26M 8.15M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.53M 1.36M -31.57370M 0.76M 0.00100M
Deferred long term asset charges - - - - -
Non current assets total 7.63M 10.81M 31.57M 4.17M 4.08M
Capital lease obligations 2.60M 0.92M - 0.88M 1.92M
Long term debt total - - 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -19.33200M -99.10000M -1.17400M -0.84700M -1.79461M
Change to liabilities 0.03M -1.03000M -0.69300M 2.44M 2.24M
Total cashflows from investing activities -19.33200M -99.36400M -1.17400M -0.84700M -1.22700M
Net borrowings - -0.00200M -0.01100M -0.04200M -0.06200M
Total cash from financing activities 0.90M 88.17M 64.05M 77.06M 28.92M
Change to operating activities -0.45800M 10.74M -4.51900M 0.09M 2.31M
Net income -26.66500M -34.60293M -26.58300M -42.03000M -24.62408M
Change in cash -37.54800M 40.96M 37.11M 53.47M 9.92M
Begin period cash flow 55.71M 106.99M 73.84M 20.37M 10.38M
End period cash flow 18.16M 147.96M 110.95M 73.84M 20.30M
Total cash from operating activities -19.09000M -24.82432M -25.90100M -22.74700M -19.24928M
Issuance of capital stock 0.00000M - 69.11M 81.70M 31.54M
Depreciation 0.57M 0.93M 0.71M 0.47M 0.26M
Other cashflows from investing activities -18.88000M -49.55000M - - -
Dividends paid - - - - -
Change to inventory -0.37100M -0.19819M -0.74500M -0.46800M 0.07M
Change to account receivables -0.39500M -1.64193M -1.39900M -0.72900M -0.72900M
Sale purchase of stock 0.90M 0.00700M 69.17M 82.18M 45.49M
Other cashflows from financing activities 0.90M 88.17M -5.04600M -4.60300M -2.57706M
Change to netincome 7.87M 7.51M 6.85M 17.49M 2.31M
Capital expenditures 0.53M 0.67M 1.17M 0.85M 1.26M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.19600M -1.84011M -7.35600M 1.33M 3.35M
Stock based compensation 7.00M 8.71M 5.66M 16.59M 1.95M
Other non cash items 1.21M 1.98M 1.66M 0.90M 0.06M
Free cash flow -19.61500M -25.49458M -27.07500M -23.59400M -20.50611M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVH
Avita Therapeutics Inc		 -0.15 5.75% 2.46 - 149.25 5.96 51.90 3.85 -10.0538
COH
Cochlear Ltd		 0.85 0.32% 268.81 47.28 38.61 7.55 9.40 7.54 29.16
PNV
Polynovo Ltd		 -0.04 3.51% 1.10 121.70 58.82 7.27 11.30 8.14 207.54
EBR
Ebr Systems Inc CDR		 -0.16 8.82% 1.66 - - - 17.76 - -3.6785
IMR
Imricor Medical Systems Inc		 -0.025 1.75% 1.40 - - 490.79 3.97 278.44 -2.6027

Reports Covered

Stock Research & News

View All

Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Avita Therapeutics Inc

28159 Avenue Stanford, Valencia, CA, United States, 91355

  • (661) 367-9170
  • Employees : 260

Key Executives

Name Title Year Born
Mr. James M. Corbett CEO, Pres & Exec. Director 1958
Mr. Michael Bria Holder MBA Chief Financial Officer 1963
Ms. Kathy M. McGee Chief Operating Officer 1966
Mr. Andrew Quick Chief Technology Officer 1971
Ms. Donna Shiroma Gen. Counsel & Sec. 1962
Ms. Erin Liberto Chief Commercial Officer 1975
Mr. David Fencil VP of Global Operations NA
Ms. Debbie Garner VP of Global Marketing NA
Mr. James M. Corbett CEO, President & Executive Director 1958
Ms. Donna Shiroma General Counsel & Secretary 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

Market Research
ISO Certified pcidss

Kalkine Solutions Private Limited, an authorized representative of Kalkine Pty Ltd, holds the ISO 27001:2022 certification (Certificate No. IC-IS-2404072) and the PCI-DSS Version 4.0 Level 1 certification (Certificate No. CSNL1PCI8067).

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2025 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.